Posted by Michael Wonder on 24 Jun 2022
European Commission approves Filsuvez for the treatment of dystrophic and junctional epidermolysis bullosa
23 June 2022 - Filsuvez will be the first and only approved treatment for epidermolysis bullosa patients.
Amryt is pleased to announce the European Commission approval of Filsuvez in the European Union for the treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in patients 6 months and older.
